Dr Jason Slingsby joined LifeArc as Chief Business Officer in May 2023.
He is responsible for developing, leading, and implementing LifeArc’s business development and partnering strategies, playing a critical part in delivering our long-term vision, to drive early-stage innovation towards patient impact.
Jason joined LifeArc from Oxford Biomedica, where he held a number of senior roles, latterly serving as Chief Business and Corporate Development Officer. Jason was responsible for M&A, spin-outs, restructurings and other strategic business transactions to drive revenue growth and geographical expansion.
He led the acquisition of Homology Medicines’ manufacturing business in 2022, which introduced Oxford Biomedica to the US market, and was responsible for establishing and maintaining commercial relationships with pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and Novartis. He chaired joint steering committees for strategic pharmaceutical partnerships and negotiated manufacturing agreements with AstraZeneca for the commercial supply of over 100m Covid-19 vaccine doses to the UK and EU.
Jason was also previously founder and CEO of ProtAffin AG, a clinical stage university spin-out based in Austria & the UK. Jason holds a degree in Biochemistry from the University of Oxford, a PhD from Imperial College London in Genetics and an MBA from London Business School.